The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2022 | Managing and treating renal impairment in multiple myeloma
In this video, Joan Bladé, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the management and treatment of renal impairment in patients with multiple myeloma. Prof. Bladé first highlights the poorer outcomes associated with patients who present with severe renal impairment, and then discusses potential treatment combinations, including bortezomib plus dexamethasone and a third agent. Following this, Prof. Bladé shares some insights into his presentation at COMy 2022, which focused on a long-term follow-up of patients with renal impairment and the improvements that have been made in these patients over the last 50 years. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
Disclosures
Honoraria for lectures: Janssen, BMS, Amgen, Takeda, Oncopeptides
